TRT on TikTok: separating bodybuilding lore from clinical fact

What did @daviddemesquita actually say?

The core argument here is that keeping total weekly androgens under 200mg, by mixing testosterone with primobolan (methenolone enanthate), limits cardiovascular risk, specifically left ventricular hypertrophy and elevated hematocrit. He claims his personal stack of 120mg testosterone plus 30mg primobolan cut his estrogen "almost in half" without an aromatase inhibitor. He also suggests that 400mg total androgens per week can be run "for a year period of time" without significant lab impact for some men.

The framing positions primobolan as a cleaner substitute for excess testosterone, reducing aromatization while filling out the androgen load. He's careful to say he's not recommending blasting, but the practical advice here, run up to 400mg for a year, goes well beyond standard TRT dosing and deserves scrutiny.

Does the science back this up?

Partially, but the cardiovascular picture is more complicated than a simple milligram threshold suggests. The claim that primobolan reduces estrogen conversion is pharmacologically sound. Primobolan has low aromatase affinity, so substituting it for testosterone does reduce total estrogen output. That part checks out.

The 200mg threshold idea is murkier. Hematocrit elevation is dose-dependent, but it's also individual, influenced by genetics, injection frequency, route of administration, and baseline erythropoiesis. There is no clean clinical evidence establishing 200mg as a universal safety cutoff. Studies like Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed hematocrit rises with supraphysiologic testosterone doses, but individual variation is wide.

Left ventricular hypertrophy is a longer-term concern tied to androgenic load and blood pressure, not just hematocrit. Research by Baggish et al. (2017, Circulation: Heart Failure) found that long-term anabolic-androgenic steroid users had significantly worse cardiac function than non-users, and primobolan is not exempt from androgenic cardiac effects. Treating any anabolic steroid as cardiovascularly neutral because it doesn't aromatize is an oversimplification the data does not support.

What did they get wrong (or right)?

Credit where it's due: the observation that primobolan lowers estrogen by reducing aromatizable substrate is real physiology. Using it as an alternative to an aromatase inhibitor is a genuine strategy some clinicians discuss, and his personal lab comparison is at least self-consistent evidence, even if n=1.

What's wrong: the implied safety of 400mg total androgens per week for "a year period of time" for "most men" is not supported by clinical literature. That dose is well into supraphysiologic territory. The statement that some guys don't see "much impact" on labs is not the same as saying there is no harm. Cardiac remodeling can occur without abnormal standard bloodwork. Achar et al. (2010, American Family Physician) noted that echocardiographic changes in AAS users often precede detectable lab abnormalities.

The 200mg total androgen threshold is also presented as established clinical consensus when it isn't. It reads more like a community heuristic than a research-derived cutoff. That distinction matters when 50,000 people are watching.

What should you actually know?

Primobolan is not a cardiac-neutral drug just because it doesn't convert to estrogen. All androgens, including low-aromatizing ones, can contribute to left ventricular hypertrophy through androgen receptor-mediated mechanisms. The absence of estrogen conversion is not the same as the absence of risk.

Running labs is genuinely good advice, but standard lipid panels and complete blood counts miss early cardiac remodeling. Anyone using supraphysiologic androgen doses long-term would need cardiac imaging, specifically echocardiography, to actually assess ventricular wall thickness and ejection fraction. Blood pressure monitoring matters too, independent of hematocrit.

Hematocrit thresholds used in TRT clinical guidelines, typically flagging concern above 54%, apply to medically supervised testosterone therapy at physiologic replacement doses. Extrapolating those thresholds to stacks at two to three times replacement dose is not clinically validated.

• No dose of androgens is inherently safe based on milligram totals alone.
• Individual response variation means "most men" is not a reliable safety standard for any given person.
• Anyone on testosterone therapy of any kind should be monitored by a licensed provider, with labs and clinical assessment, not social media benchmarks.